Lipocine Inc. · NASDAQ:LPCN

Lipocine — Investor Presentation (March 2026)

4 slides from Lipocine's investor presentation, March 2026

  1. Slide 1: LPCN 2201 Oral Brexanolone for Major Depressive Disorder (MDD)

    LPCN 2201 Oral Brexanolone for Major Depressive Disorder (MDD)

  2. Slide 2: MDD Market Potential

    MDD Market Potential Total annual burden of medication-treated MDD among the US population was $92.7 billion1 Severe MDD is strongly linked to significant difficulty in work, social, and home activities Significant Unmet Needs in Depression Disorders MDD prevalence 8.4% Rapid Relief Hours/Days, espe

  3. Slide 3: LPCN 2201 – Targeted Attribute-Based Product Differentiation

    LPCN 2201 – Targeted Attribute-Based Product Differentiation Potential Rapid Acting Anti-depressant (RAAD) Product Attribute* LPCN 2201 SPRAVATO AUVELITY SSRI/SNRI (Neuroactive Steroid) (Esketamine)1 (Dextromethorphan + bupropion)2 Serotonin reuptake inhibition NMDA receptor antagonist + (SSRI) or s

  4. Slide 4: LPCN 2201 – Oral RAAD for Major Depression Disorders

    LPCN 2201 – Oral RAAD for Major Depression Disorders Potential to set rapid relief benchmark for MDD Attributes High unmet need for oral RAAD; large market potential LPCN 2201 Rapid Relief Leverage expertise/credibility and investment/value in oral NAS created to date Convenient Oral At-Home Use Str

Lipocine — Investor Presentation (March 2026) on 6ix